Who owns TAKEDA PHARMACEUTICAL CO LTD?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of TAK from SEC Form 13F filings across 379 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 379 institutions disclosed 104.2M shares of TAKEDA PHARMACEUTICAL CO LTD worth $1.67B — about 3.3% of shares outstanding; the largest disclosed holder is Capital Research Global Investors. Source: SEC Form 13F filings, parsed by EvidInvest.
379
13F holders
$1.67B
value, 2026 filers
3.3%
of shares outstanding (104.2M sh)
72
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of TAK's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Capital Research Global Investors | 19.3M | $309.3M | 0.0% | 0.6% | +1.0% |
| 2 | FMR LLC | 9.6M | $153.9M | 0.0% | 0.3% | +34.9% |
| 3 | MORGAN STANLEY | 7.0M | $112.1M | 0.0% | 0.2% | +8.1% |
| 4 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 6.1M | $97.0M | 0.1% | 0.2% | -5.8% |
| 5 | GOLDMAN SACHS GROUP INC | 5.1M | $82.2M | 0.0% | 0.2% | -8.8% |
| 6 | BRANDES INVESTMENT PARTNERS, LP | 4.5M | $72.8M | 0.5% | 0.1% | +2.5% |
| 7 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 3.7M | $59.8M | 0.0% | 0.1% | +19.8% |
| 8 | BlackRock, Inc. | 3.7M | $59.1M | 0.0% | 0.1% | +16.1% |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 2.6M | $41.2M | 0.1% | 0.1% | -14.1% |
| 10 | Qube Research & Technologies LtdNEW | 2.2M | $35.4M | 0.0% | 0.1% | new |
| 11 | FIRST TRUST ADVISORS LP | 2.1M | $33.9M | 0.0% | 0.1% | +7.3% |
| 12 | D. E. Shaw & Co., Inc. | 2.0M | $32.9M | 0.0% | 0.1% | -21.3% |
| 13 | MANAGED ASSET PORTFOLIOS, LLC | 1.8M | $29.2M | 3.3% | 0.1% | +1.4% |
| 14 | NORTHERN TRUST CORP | 1.7M | $27.9M | 0.0% | 0.1% | -11.3% |
| 15 | VAN ECK ASSOCIATES CORP | 1.7M | $26.8M | 0.0% | 0.1% | -25.9% |
| 16 | ENVESTNET ASSET MANAGEMENT INC | 1.6M | $25.6M | 0.0% | 0.1% | +13.2% |
| 17 | AQR CAPITAL MANAGEMENT LLC | 1.5M | $24.5M | 0.0% | 0% | +70.6% |
| 18 | Quantinno Capital Management LP | 1.4M | $22.5M | 0.0% | 0% | +8.8% |
| 19 | WELLS FARGO & COMPANY/MN | 1.2M | $18.4M | 0.0% | 0% | +1.3% |
| 20 | MILLENNIUM MANAGEMENT LLCNEW | 1.1M | $16.8M | 0.0% | 0% | new |
| 21 | UBS Group AG | 911,319 | $14.6M | 0.0% | 0% | -66.7% |
| 22 | Crossmark Global Holdings, Inc. | 783,835 | $12.6M | 0.2% | 0% | +0.9% |
| 23 | JPMORGAN CHASE & CO | 744,916 | $11.9M | 0.0% | 0% | +64.1% |
| 24 | STIFEL FINANCIAL CORP | 722,863 | $11.6M | 0.0% | 0% | +15.0% |
| 25 | BNP PARIBAS FINANCIAL MARKETS | 714,143 | $11.4M | 0.0% | 0% | +275.0% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.